↓ Skip to main content

Bisphosphonates and other bone agents for breast cancer

Overview of attention for article published in this source, February 2012
Altmetric Badge

Mentioned by

policy
1 policy source
twitter
6 X users
facebook
1 Facebook page

Citations

dimensions_citation
192 Dimensions

Readers on

mendeley
173 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Bisphosphonates and other bone agents for breast cancer
Published by
John Wiley & Sons, Ltd, February 2012
DOI 10.1002/14651858.cd003474.pub3
Pubmed ID
Authors

Wong, Matthew HF, Stockler, Martin R, Pavlakis, Nick

Abstract

Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab, inhibit key pathways in the vicious cycle of bone metastases.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 173 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 1%
Spain 1 <1%
France 1 <1%
Canada 1 <1%
Unknown 168 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 33 19%
Student > Master 25 14%
Student > Ph. D. Student 20 12%
Other 18 10%
Student > Bachelor 15 9%
Other 30 17%
Unknown 32 18%
Readers by discipline Count As %
Medicine and Dentistry 91 53%
Agricultural and Biological Sciences 8 5%
Nursing and Health Professions 7 4%
Psychology 5 3%
Biochemistry, Genetics and Molecular Biology 3 2%
Other 13 8%
Unknown 46 27%